*ST长药
(300391)
| 流通市值：13.73亿 | | | 总市值：13.73亿 |
| 流通股本：3.50亿 | | | 总股本：3.50亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 70,574,999.01 | 45,795,675.76 | 111,625,132.67 | 101,004,271.66 |
| 营业收入 | 70,574,999.01 | 45,795,675.76 | 111,625,132.67 | 101,004,271.66 |
| 二、营业总成本 | 144,912,647.94 | 106,127,907.23 | 355,147,875.33 | 230,247,560.76 |
| 营业成本 | 67,993,403.43 | 47,500,988.09 | 118,791,058.48 | 96,028,186.66 |
| 税金及附加 | 1,148,311.44 | 614,069.95 | 2,474,641.66 | 2,009,584.06 |
| 销售费用 | 5,588,918.39 | 2,939,791.68 | 12,980,244.36 | 13,041,596.22 |
| 管理费用 | 41,777,722.83 | 19,053,546.04 | 102,594,239.69 | 52,775,025.94 |
| 研发费用 | 1,791,273.13 | 1,046,230.8 | 7,897,062.02 | 3,328,745.66 |
| 财务费用 | 26,613,018.72 | 34,973,280.67 | 110,410,629.12 | 63,064,422.22 |
| 其中:利息费用 | 26,416,943.71 | 35,220,018.1 | 111,173,734.74 | 61,345,196.06 |
| 其中:利息收入 | 9,403.97 | 3,009.72 | 61,300.42 | 584,041.47 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 0 | - |
| 加:投资收益 | 2,200,000 | 2,900,000 | -4,391,497.52 | - |
| 资产处置收益 | -10,628.26 | -101,726.14 | -303,874.08 | -495,306.54 |
| 资产减值损失(新) | -252,335.84 | - | -448,552,187.19 | -27,392,907.64 |
| 信用减值损失(新) | -69,700,418.76 | -31,953,818.21 | -634,652,760.69 | -120,018,439.53 |
| 其他收益 | 616,211.88 | 315,367.93 | 627,652.88 | 520,871.33 |
| 四、营业利润 | -141,484,819.91 | -89,172,407.89 | -1,330,795,409.26 | -276,629,071.48 |
| 加:营业外收入 | 91,963.2 | 65,209.47 | 148,503.87 | 30,216.67 |
| 减:营业外支出 | 467,082.08 | 289,356.56 | 97,068,868.66 | 3,499,794.72 |
| 五、利润总额 | -141,859,938.79 | -89,396,554.98 | -1,427,715,774.05 | -280,098,649.53 |
| 减:所得税费用 | -351,402.51 | - | 10,960,677.8 | 6,526.35 |
| 六、净利润 | -141,508,536.28 | -89,396,554.98 | -1,438,676,451.85 | -280,105,175.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -141,508,536.28 | -89,396,554.98 | -1,438,676,451.85 | -280,105,175.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -116,353,783.05 | -60,812,317.13 | -627,961,728.5 | -180,970,726.99 |
| 少数股东损益 | -25,154,753.23 | -28,584,237.85 | -810,714,723.35 | -99,134,448.89 |
| 扣除非经常损益后的净利润 | -116,477,762.04 | -62,639,023.43 | -569,394,644.22 | -178,898,182.2 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.33 | -0.17 | -1.79 | -0.52 |
| (二)稀释每股收益 | -0.33 | -0.17 | -1.79 | -0.52 |
| 九、综合收益总额 | -141,508,536.28 | -89,396,554.98 | -1,438,676,451.85 | -280,105,175.88 |
| 归属于母公司股东的综合收益总额 | -116,353,783.05 | -60,812,317.13 | -627,961,728.5 | -180,970,726.99 |
| 归属于少数股东的综合收益总额 | -25,154,753.23 | -28,584,237.85 | -810,714,723.35 | -99,134,448.89 |
| 公告日期 | 2025-08-26 | 2025-04-28 | 2025-04-21 | 2024-10-30 |
| 审计意见(境内) | | | 带强调事项段的无保留意见 | |